SCHEMBL596161

SCHEMBL596161

O=C(O)c1cc(O)ccn1.O=C(O)c1cc(O)ccn1.O=C(O)c1cc(O)ccn1.O=C(O)c1cc(O)ccn1.[Eu]

nearest known ligand 0.61

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KDM4E B2RXH2 8/20 0.61
ALDH1A1 P00352 5/20 0.61
KDM5A P29375 2/20 0.61
KDM3A Q9Y4C1 2/20 0.61
ASPH Q12797 2/20 0.61
KDM8 Q8N371 2/20 0.61
KDM6B O15054 1/20 0.61
TET3 O43151 1/20 0.61
KDM4A O75164 1/20 0.61
BBOX1 O75936 1/20 0.61
MAPT P10636 1/20 0.61
KDM5C P41229 1/20 0.61
KDM4D Q6B0I6 1/20 0.61
TET2 Q6N021 1/20 0.61
ALKBH5 Q6P6C2 1/20 0.61
KDM7A Q6ZMT4 1/20 0.61
TET1 Q8NFU7 1/20 0.61
EGLN2 Q96KS0 1/20 0.61
FTO Q9C0B1 1/20 0.61
EGLN1 Q9GZT9 1/20 0.61

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL29951101 0.98 KDM4E (0.63) KDM4EALDH1A1KDM5AKDM3AASPH
SCHEMBL65841 0.98 KDM4E (0.63) KDM4EALDH1A1KDM5AKDM3AASPH
SCHEMBL593577 0.96 KDM4E (0.61) KDM4EALDH1A1KDM5AKDM3AASPH
Bromide SCHEMBL9518799 0.96 KDM4E (0.61) KDM4EALDH1A1KDM5AKDM3AASPH
Water SCHEMBL961425 0.96 KDM4E (0.61) KDM4EALDH1A1KDM5AKDM3AASPH
2-Picolinic Acid SCHEMBL595042 0.89 LMNA (0.69) KDM4EALDH1A1KDM5AKDM3AASPH
Alcohol SCHEMBL28974263 0.88 KDM4E (0.53) KDM4EALDH1A1KDM5AKDM3AASPH
SCHEMBL2362971 0.87 KDM4E (0.52) KDM4EALDH1A1KDM5AKDM3AASPH
2-Picolinic Acid SCHEMBL593726 0.85 LMNA (0.69) KDM4EALDH1A1KDM5AKDM3AASPH
Quinoline SCHEMBL28452819 0.80 ALDH1A1 (0.52) KDM4EALDH1A1KDM5AKDM3AASPH

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 34 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2294159-B1 DISTANCE-CONTROLLED ENERGY TRANSFER DYE COMPLEXES INBIO PROF JUERGEN BUEDDEFELD DR PETER KLAUTH PROF MANFRED RIETZ GBR (DE) 2012-09-05 EP claimed
JP-2011525622-A 2011-09-22 JP claimed
US-20110189781-A1 DISTANCE-CONTROLLED ENERGY TRANSFER DYE COMPLEXES BÜDDEFELD, JÜRGEN, PROF (DE) 2011-08-04 US claimed
EP-2294159-A1 DISTANCE-CONTROLLED ENERGY TRANSFER DYE COMPLEXES Inbio Prof. Jürgen Büddefeld Dr. Peter Klauth Prof. Manfred Rietz Gbr (DE) 2011-03-16 EP claimed
WO-2009156019-A1 DISTANCE-CONTROLLED ENERGY TRANSFER DYE COMPLEXES INBIO PROF. JÜRGEN BÜDDEFELD DR. PETER KLAUTH PROF. MANFRED RIETZ GBR (DE) 2009-12-30 WO claimed
US-10639263-B2 Method for adjusting hardness of stick-shaped base material comprising lipid peptide compound NISSAN CHEMICAL INDUSTRIES, LTD. (JP) 2020-05-05 US disclosed
EP-3536308-A1 SKIN CARE PREPARATIONS Nisshinbo Holdings Inc. (JP) 2019-09-11 EP disclosed
US-20190254938-A1 SKIN COSMETICS NISSHINBO HOLDINGS INC. (JP) 2019-08-22 US disclosed
US-20180353414-A1 METHOD FOR ADJUSTING HARDNESS OF STICK-SHAPED BASE MATERIAL COMPRISING LIPID PEPTIDE COMPOUND NISSAN CHEMICAL INDUSTRIES, LTD. (JP) 2018-12-13 US disclosed
US-10071044-B2 Thickened composition containing lipid peptide-type compound NISSAN CHEMICAL INDUSTRIES, LTD. (JP) 2018-09-11 US disclosed
EP-3311798-A1 METHOD FOR ADJUSTING HARDNESS OF STICK-SHAPED SUBSTRATE CONTAINING LIPID-PEPTIDE-TYPE COMPOUND Nissan Chemical Industries, Ltd. (JP) 2018-04-25 EP disclosed
US-20180099051-A1 HYDROGEL-FORMING MATERIAL, PREMIX, AND HYDROGEL FORMATION METHOD NISSAN CHEMICAL INDUSTRIES, LTD. (JP) 2018-04-12 US disclosed
US-20120258059-A1 COSMETIC, EXTERNAL SKIN PREPARATION, AND MEDICAL INSTRUMENT NISSAN CHEMICAL INDUSTRIES, LTD. (JP) 2012-10-11 US disclosed
EP-2294159-B1 DISTANCE-CONTROLLED ENERGY TRANSFER DYE COMPLEXES INBIO PROF JUERGEN BUEDDEFELD DR PETER KLAUTH PROF MANFRED RIETZ GBR (DE) 2012-09-05 EP disclosed
EP-2494953-A1 COSMETIC AND EXTERNAL SKIN PREPARATION, AND MEDICAL INSTRUMENT Nissan Chemical Industries, Ltd. (JP) 2012-09-05 EP disclosed
EP-2417216-A2 MODIFICATION OF LAYERED SILICATES FOR LUMINESCENCE ACTIVATION Inbio Prof. Jürgen Büddefeld Dr. Peter Klauth Prof. Manfred Rietz Gbr (DE) 2012-02-15 EP disclosed
US-20110189781-A1 DISTANCE-CONTROLLED ENERGY TRANSFER DYE COMPLEXES BÜDDEFELD, JÜRGEN, PROF (DE) 2011-08-04 US disclosed
EP-2294159-A1 DISTANCE-CONTROLLED ENERGY TRANSFER DYE COMPLEXES Inbio Prof. Jürgen Büddefeld Dr. Peter Klauth Prof. Manfred Rietz Gbr (DE) 2011-03-16 EP disclosed
WO-2010115503-A2 MODIFICATION OF LAYERED SILICATES FOR LUMINESCENCE ACTIVATION INBIO PROF. JÜRGEN BÜDDEFELD DR. PETER KLAUTH PROF. MANFRED RIETZ GBR (DE) 2010-10-14 WO disclosed
WO-2009156019-A1 DISTANCE-CONTROLLED ENERGY TRANSFER DYE COMPLEXES INBIO PROF. JÜRGEN BÜDDEFELD DR. PETER KLAUTH PROF. MANFRED RIETZ GBR (DE) 2009-12-30 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20180099051-A1 HYDROGEL-FORMING MATERIAL, PREMIX, AND HYDROGEL FORMATION METHOD F12, CCNH, HAX1 KDM4E 4502/4885ALDH1A1 2535/4885KDM5A 4098/4885
US-20180353414-A1 METHOD FOR ADJUSTING HARDNESS OF STICK-SHAPED BASE MATERIAL COMPRISING LIPID PEPTIDE COMPOUND CUTA, F12, ARGLU1 KDM4E 2578/4885ALDH1A1 4241/4885KDM5A 4282/4885
US-10639263-B2 Method for adjusting hardness of stick-shaped base material comprising lipid peptide compound CUTA, F12, ARGLU1 KDM4E 2578/4885ALDH1A1 4241/4885KDM5A 4282/4885
US-20120258059-A1 COSMETIC, EXTERNAL SKIN PREPARATION, AND MEDICAL INSTRUMENT CUTA, F12, SGMS1 KDM4E 4273/4885ALDH1A1 2771/4885KDM5A 4445/4885
US-10071044-B2 Thickened composition containing lipid peptide-type compound NGLY1, APOB, C9 KDM4E 4546/4885ALDH1A1 3571/4885KDM5A 4463/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.